Kailos Genetics, LLC. products

Kailos Iota combines TargetRich, our foundational genetic enrichment technology, with next-generation sequencing and statistical machine learning that results in a highly specific cancer assay of multiple solid tumors at all stages. The Iota assay detects methylation differences in a person’s blood sample, the superior choice for early disease detection. The process of detecting these changes is called a methylated liquid biopsy and it can be used as a companion to standard imaging protocols such as mammograms and low dose CT scans among others. Because methylated liquid biopsies can be performed more frequently for screening, treatment and recurrence detection they are expected to improve patient outcomes and increase participation in screening programs.